Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors

Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

(2011) Elahe A. Mostaghel et al.   CLINICAL CANCER RESEARCH

Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population

(2011) W. R. Farwell et al.   JNCI-Journal of the National Cancer Institute

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Statin medication use and the risk of biochemical recurrence after radical prostatectomy

(2010) Robert J. Hamilton et al.   CANCER

Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study

(2010) G. David Batty et al.   CANCER CAUSES & CONTROL

Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy

(2010) Ruchika Gutt et al.   JOURNAL OF CLINICAL ONCOLOGY

The Association Between Statin Use and the Diagnosis of Prostate Cancer in a Population Based Cohort

(2010) Rodney H. Breau et al.   JOURNAL OF UROLOGY

Lipid Rafts As a Membrane-Organizing Principle

(2010) D. Lingwood et al.   SCIENCE

Ezetimibe Is an Inhibitor of Tumor Angiogenesis

(2009) Keith R. Solomon et al.   AMERICAN JOURNAL OF PATHOLOGY

Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort

(2009) Alison M. Mondul et al.   CANCER CAUSES & CONTROL

Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

(2009) E. A. Platz et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Serum cholesterol levels in relation to the incidence of cancer: The JPHC study cohorts

(2009) Hiroyasu Iso et al.   INTERNATIONAL JOURNAL OF CANCER

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

(2009) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

(2009) William P Harris et al.   Nature clinical practice. Urology

Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications

(2008) Elahe A. Mostaghel et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer

(2008) Robert W. Ross et al.   CANCER

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH

Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth

(2008) R. B. Montgomery et al.   CANCER RESEARCH

Androgen deprivation therapy for prostate cancer

(2008) Eric A Singer et al.   EXPERT OPINION ON PHARMACOTHERAPY

Association between plasma cholesterol and prostate cancer in the PSA era

(2008) Elizabeth A. Platz et al.   INTERNATIONAL JOURNAL OF CANCER

Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol

(2008) Paulette R. Dillard et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Do the cholesterol-lowering properties of statins affect cancer risk?

(2008) Keith R. Solomon et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

CYP17 inhibition as a hormonal strategy for prostate cancer

(2008) Alison HM Reid et al.   Nature clinical practice. Urology